Dr Reddys Laboratories has launched over the counter (OTC) Lansoprazole delayed release capsules in the US market following the company’s ANDA approval by United States Food & Drug Administration (USFDA).
The company will make the product under store brand lables in the US market. The product is the bioequivalent version of Novartis Consumer Health’s Prevacid 24 HR capsules which received Rx-to-OTC switch approval with 3 year exclusivity from the FGDA on March 18, 2009.
Recently, the company launched Clopidogrel Tablets, USP 75mg and 300mg, a bioequivalent generic version of Plavix in the US market. The ANDAs for Clopidogrel Tablets USP 75mg and 300mg are approved by the United States Food & Drug Administration (USFDA).
The company registered a growth of 27.68% in fourth quarter ended March 31, 2012 net profit at Rs 211.79 crore as compared to Rs 165.87 crore for the quarter ended March 31, 2011. Total income increased by 49.09% to Rs 2051.18 crore January-March quarter, 2012 from Rs 1375.77 crore for the similar quarter a period ago.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1814.50 |
Dr. Reddys Lab | 1341.60 |
Cipla | 1476.45 |
Lupin | 2168.25 |
Zydus Lifesciences | 972.30 |
View more.. |